Sol-Gel Technologies Ltd.
NASDAQ:SLGL
0.59 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Sol-Gel Technologies Ltd. |
Symbool | SLGL |
Munteenheid | USD |
Prijs | 0.591 |
Beurswaarde | 16,463,842 |
Dividendpercentage | 0% |
52-weken bereik | 0.334 - 1.575 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alon Seri-Levy |
Website | https://www.sol-gel.com |
An error occurred while fetching data.
Over Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)